Literature DB >> 25700649

[HDL and atherosclerotic cardiovascular diseases].

E Windler1, S Nitschmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25700649     DOI: 10.1007/s00108-015-3664-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  8 in total

Review 1.  HDL and cardiovascular disease.

Authors:  Daniel J Rader; G Kees Hovingh
Journal:  Lancet       Date:  2014-08-16       Impact factor: 79.321

2.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

3.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

4.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

5.  Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  Circulation       Date:  2013-08-21       Impact factor: 29.690

6.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

Review 7.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.

Authors:  Matthias Briel; Ignacio Ferreira-Gonzalez; John J You; Paul J Karanicolas; Elie A Akl; Ping Wu; Boris Blechacz; Dirk Bassler; Xinge Wei; Asheer Sharman; Irene Whitt; Suzana Alves da Silva; Zahira Khalid; Alain J Nordmann; Qi Zhou; Stephen D Walter; Noah Vale; Neera Bhatnagar; Christopher O'Regan; Edward J Mills; Heiner C Bucher; Victor M Montori; Gordon H Guyatt
Journal:  BMJ       Date:  2009-02-16

8.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

Authors:  Benjamin F Voight; Gina M Peloso; Marju Orho-Melander; Ruth Frikke-Schmidt; Maja Barbalic; Majken K Jensen; George Hindy; Hilma Hólm; Eric L Ding; Toby Johnson; Heribert Schunkert; Nilesh J Samani; Robert Clarke; Jemma C Hopewell; John F Thompson; Mingyao Li; Gudmar Thorleifsson; Christopher Newton-Cheh; Kiran Musunuru; James P Pirruccello; Danish Saleheen; Li Chen; Alexandre F R Stewart; Arne Schillert; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Sonia Anand; James C Engert; Thomas Morgan; John Spertus; Monika Stoll; Klaus Berger; Nicola Martinelli; Domenico Girelli; Pascal P McKeown; Christopher C Patterson; Stephen E Epstein; Joseph Devaney; Mary-Susan Burnett; Vincent Mooser; Samuli Ripatti; Ida Surakka; Markku S Nieminen; Juha Sinisalo; Marja-Liisa Lokki; Markus Perola; Aki Havulinna; Ulf de Faire; Bruna Gigante; Erik Ingelsson; Tanja Zeller; Philipp Wild; Paul I W de Bakker; Olaf H Klungel; Anke-Hilse Maitland-van der Zee; Bas J M Peters; Anthonius de Boer; Diederick E Grobbee; Pieter W Kamphuisen; Vera H M Deneer; Clara C Elbers; N Charlotte Onland-Moret; Marten H Hofker; Cisca Wijmenga; W M Monique Verschuren; Jolanda M A Boer; Yvonne T van der Schouw; Asif Rasheed; Philippe Frossard; Serkalem Demissie; Cristen Willer; Ron Do; Jose M Ordovas; Gonçalo R Abecasis; Michael Boehnke; Karen L Mohlke; Mark J Daly; Candace Guiducci; Noël P Burtt; Aarti Surti; Elena Gonzalez; Shaun Purcell; Stacey Gabriel; Jaume Marrugat; John Peden; Jeanette Erdmann; Patrick Diemert; Christina Willenborg; Inke R König; Marcus Fischer; Christian Hengstenberg; Andreas Ziegler; Ian Buysschaert; Diether Lambrechts; Frans Van de Werf; Keith A Fox; Nour Eddine El Mokhtari; Diana Rubin; Jürgen Schrezenmeir; Stefan Schreiber; Arne Schäfer; John Danesh; Stefan Blankenberg; Robert Roberts; Ruth McPherson; Hugh Watkins; Alistair S Hall; Kim Overvad; Eric Rimm; Eric Boerwinkle; Anne Tybjaerg-Hansen; L Adrienne Cupples; Muredach P Reilly; Olle Melander; Pier M Mannucci; Diego Ardissino; David Siscovick; Roberto Elosua; Kari Stefansson; Christopher J O'Donnell; Veikko Salomaa; Daniel J Rader; Leena Peltonen; Stephen M Schwartz; David Altshuler; Sekar Kathiresan
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.